hcplive.com
Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Clinicians, Patients On Biologics, and Adult patients following Crohn's disease, Inflammatory bowel disease, Risankizumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be an observational study related to Crohn's disease, Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. Use the original source link for the full details.
Study details such as design, patient population, comparison group, and measured outcomes matter. The original source has the full context.
